Does ALNYLAM PHARMACEUTICALS, INC. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores ALNYLAM PHARMACEUTICALS, INC. (ALNY) 39.0 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 96, returns on capital 0, balance-sheet safety 28, capital discipline 24.

How has ALNY's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 39.0 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

ALNYLAM PHARMACEUTICALS, INC.

ALNY · Healthcare · $35.4B mkt cap · FY2025 filings · No moat ·

Doesn't clear the bar

No moat

The four filters

Pricing power96

Median gross margin 86.4% over 9y, very stable.

Returns on capital0

Median ROIC -73.0%, above the 9% hurdle in 0% of years.

Balance-sheet safety28

Net debt/EBITDA n/ax, interest coverage 2x.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $267.47
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

19 years of fundamentals

The business, in plain English

ALNYLAM PHARMACEUTICALS, INC. booked $3.7B of revenue in FY2025 in the Healthcare sector and kept 81.8% of it as gross profit — a high-margin business by that measure. After every other cost, 8.4% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $96.2M (FY2008) to $3.7B (FY2025) — about 24.0% a year compounded over 17 years.

It earned −125.9% on invested capital in FY2020, with a median of −73.0% across 13 filed years. The Returns on Capital filter above scores it 0/100.

ALNY's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.

The share count rose 216.4% between FY2009 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.

Put together: Pricing Power is the strongest of the four filters (96/100) and Returns on Capital the weakest (0/100), which is how ALNY lands at 39/100 — a None moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$3.7B FY2025

Gross marginRevenue kept after cost of goods81.8% FY2025

Return on invested capitalOperating profit on the capital employed−125.9% FY2020

Owner earningsCash an owner could take out$313.7M FY2025

Gaps in a line mean that item isn’t in ALNY’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale39.0 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — ALNY has read No moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#261 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#259LH LABCORP HOLDINGS INC.39.1 out of 100, No moatNo moat
#260CTSO CYTOSORBENTS CORPORATION39.1 out of 100, No moatNo moat
#262NUWE Nuwellis, Inc.38.9 out of 100, No moatNo moat
#263TRNS TRANSCAT INC38.8 out of 100, No moatNo moat

Compare ALNY with its nearest peers →All Healthcare companies on the Index →

Common questions about ALNY

Does ALNYLAM PHARMACEUTICALS, INC. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores ALNYLAM PHARMACEUTICALS, INC. (ALNY) 39.0 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 96, returns on capital 0, balance-sheet safety 28, capital discipline 24.
How has ALNY's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 39.0 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows ALNY’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/ALNY"
  width="340" height="150" style="border:0"
  title="ALNY Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell ALNY. See the disclaimer.